U.S. Senator Elizabeth Warren Writes FTC To Express Concern About Two Pharmaceutical Deals; Warren Tells Agency She Is "Particularly Concerned" About Amgen Plan To Buy Horizon Therapeutics And Indivior's Plan To Buy Opiant Pharmaceuticals
- Reuters
- Reuters
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/7/2024 | $320.00 → $335.00 | Overweight → Equal Weight | Wells Fargo | |
5/3/2024 | $230.00 → $300.00 | Underweight → Equal Weight | Barclays | |
5/3/2024 | Mkt Perform → Outperform | William Blair | ||
3/28/2024 | Mkt Perform | Raymond James | ||
2/28/2024 | Buy → Neutral | Ladenburg Thalmann | ||
2/7/2024 | $324.00 → $318.00 | Outperform → Market Perform | Leerink Partners | |
1/8/2024 | $11.00 | Neutral → Sell | B. Riley Securities | |
12/21/2023 | $264.00 → $320.00 | Neutral → Buy | Daiwa Securities |
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13D - AMGEN INC (0000318154) (Filed by)
40-17G - Horizon Technology Finance Corp (0001487428) (Filer)
10-Q - AMGEN INC (0000318154) (Filer)
8-K - AMGEN INC (0000318154) (Filer)
Wells Fargo downgraded Amgen from Overweight to Equal Weight and set a new price target of $335.00 from $320.00 previously
Barclays upgraded Amgen from Underweight to Equal Weight and set a new price target of $300.00 from $230.00 previously
William Blair upgraded Amgen from Mkt Perform to Outperform
Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona. The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities. "The breadth of these data reflects our strategy to advance diverse modalities for difficult-to-treat cancers," said Jay Bradner, M.D., executive vice president,
TEMPE, Ariz., Sept. 12, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. ("GT MedTech" or the "Company"), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced it has secured a $35 million venture loan facility, of which $15 million has been initially funded from Horizon Technology Finance Corporation (NASDAQ:HRZN), an affiliate of Monroe Capital. The Company will use the loan proceeds to execute strategic commercial and clinical expansion plans for GammaTile®. These initiatives will drive key corporate object
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to GT Medical Technologies, Inc. ("GT MedTech"), of which $15 million has been initially funded. GT MedTech, through its innovative flagship product, GammaTile®, offers a proprietary solution to treat brain tumors. GammaTile is a bioresorbable collagen tile embedded with radiation seeds
Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:
Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Submission status for AMGEN INC's drug AMJEVITA (SUPPL-19) with active ingredient ADALIMUMAB-ATTO has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 761024, Application Classification:
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona. The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities. "The breadth of these data reflects our strategy to advance diverse modalities for difficult-to-treat cancers," said Jay Bradner, M.D., executive vice president,
First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population. "For the first time, children and adolescent
THOUSAND OAKS, Calif., Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the second quarter, total revenues increased 20% to $8.4 billion in comparison to the second quarter of 2023.Product sales grew 20%, driven by 26% volume growth, partially offset by 3% lower net selling price. Excluding sales from our Horizon Therapeutics (Horizon) acquisition, product sal
Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Amgen. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 58% leaning bullish and 33% bearish. Among these notable options, 3 are puts
- Reuters
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted by 6.3%, marking their worst daily performance since March 2021. In the last two sessions, they have dropped by over 10%, registering the worst two-day downside since March 2020. Similarly, shares of Dutch pharmaceutical giant Novo Nordisk A/S fell 4%. Chart: Eli Lilly’s Worst Session In Over Three Years Image: Benzinga Pro Weight-Loss Market Sees New Entrants “This week is a pr
Vesta Healthcare, a virtual care provider group for people with home care, today announced the close of $65 million in a Series C round with new debt financing. The equity round was led by Boston-based RA Capital Management, with participation from Oak HC/FT, Chrysalis Ventures, CareCentrix/Walgreens, Nationwide, Kaiser Permanente Ventures, Lux Capital, Generator Ventures, Deerfield Management and others. Debt financing was provided by Horizon Technology Finance Corporation, an affiliate of Monroe Capital. "The home is the last frontier of healthcare, and caregivers are the most vital yet disconnected resource in the delivery system," said Randy Klein, CEO of Vesta Healthcare. "We're pr
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press